WEBULL
News
PRTA
11.11
-0.45%
-0.05
H.C. Wainwright Remains a Buy on Prothena (PRTA)
TipRanks · 1d ago
Prothena Highlights Advances in Protein Dysregulation Therapies for Neurodegenerative Diseases in Latest Presentation
Reuters · 3d ago
Amazon To Rally Around 31%? Here Are 10 Top Analyst Forecasts For Monday
Benzinga · 4d ago
Prothena Is Maintained at Market Outperform by Citizens
Dow Jones · 4d ago
Prothena Price Target Raised to $19.00/Share From $11.00 by Citizens
Dow Jones · 4d ago
Citizens Maintains Market Outperform on Prothena Corp, Raises Price Target to $19
Benzinga · 4d ago
Prothena price target raised to $19 from $11 at Citizens JMP
TipRanks · 4d ago
Weekly Report: what happened at PRTA last week (1124-1128)?
Weekly Report · 4d ago
Prothena price target raised to $8 from $4 at BofA
TipRanks · 11/24 14:16
Sell Rating for Prothena Due to Reliance on Partnered Programs and Uncertainties in Phase 3 Trials
TipRanks · 11/24 11:26
Weekly Report: what happened at PRTA last week (1117-1121)?
Weekly Report · 11/24 10:07
Promising Outlook for Prothena: Buy Rating Backed by Innovative CYTOPE Platform Advancements
TipRanks · 11/20 14:25
Piper Sandler Reaffirms Their Buy Rating on Prothena (PRTA)
TipRanks · 11/20 11:37
Prothena Shareholders Approve Capital Reduction Proposal
TipRanks · 11/19 22:06
BRIEF-Prothena Announces Poster Presentation On Its TDP-43 Cytope® Program At Neuroscience 2025
Reuters · 11/19 21:38
Prothena Corporation plc Held Extraordinary General Meeting
Reuters · 11/19 21:31
Prothena announces poster presentation on TDP-43 CYTOPE program
TipRanks · 11/19 21:10
Prothena Data From TDP-43 CYTOPE Program Demonstrates CYTOPE Technology's Potential To Deliver Large Molecules Into Cells
Benzinga · 11/19 21:09
Prothena Unveils Promising Preclinical Results for TDP-43 CYTOPE in ALS Mouse Model
Reuters · 11/19 21:06
Prothena Announces Poster Presentation on its TDP-43 CYTOPE® Program at Neuroscience 2025
Barchart · 11/19 15:05
More
Webull provides a variety of real-time PRTA stock news. You can receive the latest news about Prothena through multiple platforms. This information may help you make smarter investment decisions.
About PRTA
Prothena Corporation plc is an Ireland-based late-stage clinical biotechnology company. The Company is engaged in protein dysregulation and a pipeline of investigational therapeutics for rare peripheral amyloid diseases. The Company is advancing a pipeline of therapeutic candidates for a range of indications and targets to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins. The Company’s pipeline includes both wholly owned and partnered programs being developed for the potential treatment of diseases, including AL amyloidosis, ATTR amyloidosis, Alzheimer’s disease, Parkinson’s disease and a range of other neurodegenerative diseases. Its clinical programs include birtamimab for the potential treatment of AL amyloidosis, prasinezumab for the potential treatment of Parkinson’s disease, NNC6019/PRX004 for the potential treatment of ATTR amyloidosis, and PRX005 and PRX012 for the potential treatment of Alzheimer’s disease.